3 results
Approved WMOCompleted
To assess the efficacy of the co-administration of lanreotide Autogel 120 mg(administered via deep sub-cutaneous injections every 28 days) and pegvisomant(administered at 40 to 120 mg per week via sub-cutaneous injection given once ortwice a week)…
Approved WMOCompleted
The purpose of this study is to confirm the safety and performance of the BioMatrix CRD for the repair of focal articular cartilage lesions or osteochondral defects in the knee.
Approved WMOPending
Primary Objective: • To evaluate the ability to concentrate the radiotracer in prostatic cancer lesions ( with respect to accumulation in background tissues) by prostatic artery injection (PAI), especially within the prostate gland compared to…